Study of SHR-1703 for eosinophilic granulomatosis with polyangiitis (EGPA)
Treatments studied
Part of Blood & lymphatic, Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests a new medicine called SHR-1703 for people with EGPA that has come back or is hard to treat. It aims to see if the drug can help control the disease better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with EGPA for at least 6 months.
- Your EGPA has come back or is not well controlled with current treatment.
- You take prednisone (a steroid) every day at a dose between 7.5 mg and 50 mg for at least 4 weeks before joining.
- You are not currently taking cyclophosphamide or certain other strong immune-suppressing drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the health course of people who have eosinophilic granulomatosis with polyangiitis, a rare inflammatory condition. Your participation may help researchers better understand how the illness changes over time.
This trial tests reslizumab, a medicine that targets a specific immune signal, to improve symptoms in people with eosinophilic granulomatosis with polyangiitis (EGPA). It may help lower disease activity and reduce inflammation-related problems.
This trial tests a new medicine called SHR-1703 for people with eosinophilic asthma (a type of asthma with high levels of certain white blood cells). It looks at how safe the medicine is over time and if it helps control asthma attacks. You must already be using medium or high dose inhaled steroids plus another asthma medicine, and have had at least one asthma attack in the past year.
This study looks at inflammation in the ear, nose, and throat area in people with different conditions, including nasal polyps, severe asthma, eGPA (a rare blood vessel disease), and GPA (another rare disease). It compares them to healthy volunteers to better understand what causes local inflammation.
This trial tests a medicine called benralizumab for children with specific eosinophil-driven diseases (EGPA or HES). It aims to see if the drug can help control these conditions.
This trial tests two ways to give the study drug SHR-1703: a pre-filled syringe and an autoinjector. Healthy participants will help see if both devices work safely and similarly.
Hear when a new Eosinophilic Granulomatosis With Polyangiitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.